G. K. Butterfield actually said...
The Pediatric PRV Program addressed the market failures we have seen as rare pediatric disease drugs have struggled to market by creating financial incentives for rare pediatric disease drug development in the form of vouchers.
Context
Butterfield advocates for the Pediatric Priority Review Voucher Program to support rare disease drug development.
04/29/2015